Contribution: Industrial Research Assistance Program – Contributions to Firms
Nanofacile inc.
$75,000.00
AI-guided high-throughput platform for developing encapsulated therapeutics
EF 2025-26 · 2025-09-01
Résumé
Development and commercialization readiness of an AI-driven high-throughput platform for therapeutic nanoparticle formulation, combining an innovative pumpless consumable with an intelligent software assistant.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Montreal|Montréal, Quebec, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
796600351
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 60 days. The total amended value is 75,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 60 jours. La valeur totale des modifications est de 75 000 dollars.
Agreement End Date
2026-05-29
Agreement Number
1034991
Agreement Start Date
2025-09-01
Agreement Title
AI-guided high-throughput platform for developing encapsulated therapeutics
Agreement Title (French)
Plateforme à haut débit guidée par l’IA pour le développement de thérapies encapsulées
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Date
2025-12-04
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Development and commercialization readiness of an AI-driven high-throughput platform for therapeutic nanoparticle formulation, combining an innovative pumpless consumable with an intelligent software assistant.
Description (French)
Développement et mise en place commerciale d’une plateforme à haut débit guidée par l’IA pour la formulation de nanoparticules thérapeutiques, combinant un consommable innovant sans pompe avec un assistant logiciel intelligent.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding (French)
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number
24077
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
796600351
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Nanofacile inc.
Recipient Operating Name
Nanofacile Inc.
Recipient Postal Code
H3C 0B4
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2025-2026-Q3-1034991
